The estimated Net Worth of Wesley Johnson is at least $1.16 Million dollars as of 15 July 2022. Mr. Johnson owns over 6,022 units of Angiodynamic Inc stock worth over $636,087 and over the last 18 years he sold ANGO stock worth over $293,320. In addition, he makes $228,008 as Independent Director at Angiodynamic Inc.
Wesley has made over 11 trades of the Angiodynamic Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 6,022 units of ANGO stock worth $96,051 on 15 July 2022.
The largest trade he's ever made was exercising 14,000 units of Angiodynamic Inc stock on 22 June 2018 worth over $189,420. On average, Wesley trades about 2,796 units every 76 days since 2007. As of 15 July 2022 he still owns at least 85,726 units of Angiodynamic Inc stock.
You can see the complete history of Mr. Johnson stock trades at the bottom of the page.
Wesley E. Johnson, Jr. serves as an Independent Director of the Company. Since February 2013, Mr. Johnson has been Chief Executive Officer and Director of Admittance Technologies, Inc., a medical device company. Mr. Johnson is also a director of Minimus Spine, Inc., a private medical device company. From 2003 to 2007, Mr. Johnson served as a member of the board of RITA Medical Systems, Inc. and Chairman of its Audit Committee. From February 2008 to May 2012, Mr. Johnson served as President, CEO and Director of Cardiokinetix, Inc., a developer of medical devices for the treatment of congestive heart failure. From October 2005 to February 2008, Mr. Johnson served as General Manager of Abbott Spine, S.A., a division of Abbott Laboratories. From June 2003 to October 2005, Mr. Johnson served as Division Vice President, Finance for Abbott Spine. From May 1999 to June 2003, he served as Vice President of Operations and Chief Financial Officer for Spinal Concepts. Mr. Johnson holds a B.B.A. in Accounting from Texas A&M University and became a certified public accountant in 1981. Mr. Johnson is chairman of our Nominating, Compliance and Corporate Governance Committee and a member of our Audit Committee.
As the Independent Director of Angiodynamic Inc, the total compensation of Wesley Johnson at Angiodynamic Inc is $228,008. There are 13 executives at Angiodynamic Inc getting paid more, with James Clemmer having the highest compensation of $3,116,630.
Wesley Johnson is 62, he's been the Independent Director of Angiodynamic Inc since 2007. There are 1 older and 25 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.
Wesley's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman, and Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: